Clinical trial NCT00246961: Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Official title: Arimidex: Reason for and Effect of Change From Tamoxifen
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Adjuvant
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-11-01
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.


Eligibility criteria: Inclusion Criteria:

* Postmenopausal
* Hormone sensitive breast cancer
* Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion Criteria:

* Visceral metastases
* Patients with signs of progression at the moment of changing therapy
* Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: 'S-Gravenhage
country: Netherlands
facility: Research Site
city: 's-Hertogenbosch
country: Netherlands
facility: Research Site
city: Alkmaar
country: Netherlands
facility: Research Site
city: Antwerpen
country: Netherlands
facility: Research Site
city: Apeldoorn
country: Netherlands
facility: Research Site
city: Bergen op Zoom
country: Netherlands
facility: Research Site
city: Boxmeer
country: Netherlands
facility: Research Site
city: Breda
country: Netherlands
facility: Research Site
city: Doetinchem
country: Netherlands
facility: Research Site
city: Dordrecht
country: Netherlands
facility: Research SIte
city: Ede
country: Netherlands
facility: Research Site
city: Eindhoven
country: Netherlands
facility: Research Site
city: Enschede
country: Netherlands
facility: Research Site
city: Geldrop
country: Netherlands
facility: Research Site
city: Groningen
country: Netherlands
facility: Research Site
city: Harderwijk
country: Netherlands
facility: Research Site
city: Helmond
country: Netherlands
facility: Research Site
city: Hoogeveen
country: Netherlands
facility: Research Site
city: Hoorn
country: Netherlands
facility: Research Site
city: Leiden
country: Netherlands
facility: Research Site
city: Oosterhout
country: Netherlands
facility: Research Site
city: Purmerend
country: Netherlands
facility: Research Site
city: Roermond
country: Netherlands
facility: Research Site
city: Roosendaal
country: Netherlands
facility: Research Site
city: Rotterdam
country: Netherlands
facility: Research Site
city: Schiedam
country: Netherlands
facility: Research Site
city: Terneuzen
country: Netherlands
facility: Research Site
city: Tiel
country: Netherlands
facility: Research Site
city: Venray
country: Netherlands
facility: Research Site
city: Vlissingen
country: Netherlands
facility: Research Site
city: Winterswijk
country: Netherlands
facility: Research Site
city: Zoetermeer
country: Netherlands
facility: Research Site
city: Zutphen
country: Netherlands
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: AstraZeneca The Netherlands Medical Director, MD
role: STUDY_DIRECTOR
References: